Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617440 | 1.00 | SRD5A1 (0.61) | SRD5A1SRD5A2 | |
| SCHEMBL8925140 | 0.86 | — | — | |
| SCHEMBL8925138 | 0.86 | — | — | |
| SCHEMBL7162855 | 0.85 | SRD5A1 (0.50) | SRD5A1SRD5A2 | |
| SCHEMBL7162850 | 0.85 | SRD5A1 (0.50) | SRD5A1SRD5A2 | |
| SCHEMBL8157363 | 0.83 | SRD5A1 (0.60) | SRD5A1SRD5A2 | |
| SCHEMBL8157360 | 0.83 | SRD5A1 (0.60) | SRD5A1SRD5A2 | |
| SCHEMBL8721493 | 0.83 | SRD5A1 (0.56) | SRD5A1SRD5A2 | |
| SCHEMBL9348446 | 0.82 | SRD5A1 (0.71) | SRD5A1SRD5A2 | |
| SCHEMBL11132394 | 0.82 | SRD5A1 (0.71) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994015602-A1 | COMBINATION METHOD FOR TREATING PATTERNED ALOPECIA WITH 17β-N-SUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES AND MINOXIDIL | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | claimed |
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| US-6268376-B1 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5710275-A | ENZYME AND HORMONE INHIBITORS | MERCK & CO., INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5629318-A | Method of treatment of chronic prostatitis with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0462662-A2 | 17beta-N-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | NR5A1, CYP17A1, HSD17B7 | SRD5A1 8/4885SRD5A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.